He has significant experience advising clients on a wide variety of matters, including private M&A, joint ventures, public takeovers, restructurings and listing requirements.
Matthew has specific expertise in highly complex cross-border M&A transactions. He regularly advises clients on M&A auction processes, executing successful transactions both for sellers and for buyers.
Experience
Representative matters
Asahi Group on its USD11.3bn acquisition of Carlton & United Breweries, the Australian arm of Anheuser-Busch InBev; its EUR7.30bn acquisition of the Central & Eastern European business of SABMiller by way of auction; and on its EUR2.55bn acquisition of Peroni, Grolsch and Meantime by way of auction.
Grünenthal on its USD922m acquisition from AstraZeneca of prescription products Nexium in Europe and Vimovo worldwide (excluding the U.S. and Japan; its acquisition of the global rights to the migraine medication, Zomig, from AstraZeneca for a total consideration of up to USD302m.
A global healthcare company on various disposals of consumer healthcare products by way of auction, including its disposal to STADA of a portfolio of 15 over-the-counter consumer healthcare brands, covering multiple therapeutic areas such as cold & flu, pain and skincare and a range of product types (including medicines, food supplements, cosmetics and medical devices), across more than 40 countries.
GSK on its EUR150m investment into, and strategic collaboration with, German biotech company CureVac for the research, development and commercialisation of mRNA-based vaccines and monoclonal antibodies targeting infectious diseases.
Qualifications
Admissions
Academic
Please note that there is a known fraud/scam using this individual's name.
More information on fraud using the A&O Shearman brand can be found here.
Please contact inhouselegal@aoshearman.com if you have been contacted.
